Clik here to view.
Gilead Buys CV Therapeutics (Update 1)
The morning’s other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that it will purchase CV Therapeutics for $1.4 billion. The sudden move frees Palo...
View ArticleCalifornia Life Sciences to Partner with China
BIOCOM, a trade group representing Southern California’s life sciences industry, is ramping up partnership efforts in China to meet an emerging desire for novel drug therapies. While intellectual...
View ArticleShrinking Economy Hits California Biosector
By Amy Ritter, Pharmaeutical Technology. A report released on Feb. 8, 2012 from the California Healthcare Institute, BayBio and PwC shows that the shrinking economy, changes in investment strategies,...
View ArticleVC Funding Floods Colorado Biotechs, But Will It Stifle Innovation?
By Marylyn Donahue. Biotechs in Colorado, US, are enjoying a windfall of funding from Venture Capitalists who have to date invested $66.1 million in six of the state’s companies working in the fields...
View ArticleUncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011
Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for...
View ArticleClik here to view.
CETP Inhibitors: Blockbusters that Never Ran?
Donald McCaffery, CEO at Resverlogix The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of...
View ArticleNew York Pharma Forum: Together We Stand
Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward. It’s no secret that the...
View ArticleEurope's Bioscience 'Oscars': The Contenders
By Peter O’ Donnell. Europe’s closest thing to an Oscar’s ceremony for bioscience will take place in early October. The EuropaBio award for the most innovative European Union biotechnology firm is...
View ArticleClik here to view.
The Little Orphan That Could: How Alexion is Going Global
David Hallal, Chief Commercial Officer, Alexion Pharmaceuticals Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small...
View ArticleClik here to view.
Lessons from Biotech: Tweaking the Imperfections
Eugene Williams, CEO and Co-founder of Dart Therapeutics An increasing number of small biotech companies are being hatched to focus on a single disease or condition. The strategy goes against the...
View ArticleClik here to view.
Prove It! Top Line Thoughts on Trends That Will Shape the Industry in 2014
Top Line Thoughts on 2014: Prove It! Ten days in and the New Year already seems old. Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on...
View ArticleClik here to view.
Time for Russia to Get Serious about Biopharma
Back in 1980, the biotech industry did not exist. There was little difference between the means of production in Western markets and the socialist planned economies embodied by Russia – medicines,...
View ArticleRise in IPOs Eases Pharma's Investment Woes
Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment...
View ArticleBiotech Stocks Shaken by Fed Warning
Today’s Financial Times (FT) reports that nearly $40bn was wiped from the biotech market’s value last week (a 6 per cent drop in the Nasdaq biotechnology index) following the Federal Reserve’s...
View ArticleEuropaBio’s Most Innovative Biotechs 2014
EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be...
View ArticleSetting Biotech Standards in India
The past decade has seen considerable growth in the Indian pharmaceutical industry. The country has emerged as a key supplier of high quality and affordable medicines not only to the developing world,...
View ArticleClik here to view.
Pharma and Biotech Trends 2014
Peter Young examines the fast-moving growth drivers for the two segments and what their 2014 numbers mean for respective M&A and other strategies going forward. The pharmaceutical and biotechnology...
View Article
